Transpharma-Medical To Announce Promising Results Of Clinical Trials With Its hPTH (1-34) -Transdermal Delivery Product For Osteoporosis Treatment

Published: Mar 28, 2006

TransPharma-Medical Ltd., the Israeli-based specialty pharma company that develops pharmaceutical products based on its unique RF-MicroChannels™ transdermal drug delivery technology, announces promising results of first human clinical trials demonstrating transdermal delivery of human Parathyroid Hormone 1-34 fragment, (hPTH 1-34)for the treatment of osteoporosis.

Back to news